SGX-listed Singapore eDevelopment Limited’s (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. (“Impact”), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. Impact Biomedical’s transition to the Quantum research program comes on the heels of the completion of the research and development stage of its existing biodefense
The post Impact Biomedical initiates Quantum Research Program to solve the Patent Cliff appeared first on Pharma Mirror Magazine.
